- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Severe established osteoporosis
- Meeting Date: March 2021
- Public Summary Document (PSD) March 2021 PBAC Meeting - (PDF 856KB)
- Public Summary Document (PSD) March 2021 PBAC Meeting - (Word 50KB)
Teriparatide – March 2021
Teriparatide: Injection 250 micrograms per mL, 2.4 mL in multi-dose pre-filled cartridge; Terrosa®
Last updated
2 July 2021